BH3:ETR
PTC Therapeutics, Inc.
€59.62
arrow_downward
-0.73%(-0.44) 1D
Sep 7, 5:30:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€59.84
High
€59.84
Low
€59.62
Mkt. cap
5.78B
Avg. vol.
1.00
Volume
0.00
52-wk high
€78.18
52-wk low
€59.42
No. of employees
991
Open
€59.84
High
€59.84
Low
€59.62
Mkt. cap
5.78B
Avg. vol.
1.00
Volume
0.00
52-wk high
€78.18
52-wk low
€59.42
No. of employees
991
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com